eGFR MDRD changed | Treatment arm | Week 4 % (n) | Week 8 % (n) | Week 12 % (n) | Week 16 % (n) | Week 20 % (n) | Week 24 % (n) |
---|---|---|---|---|---|---|---|
Increased | Lithium | 30.4% (7/23) | 39.1% (9/23) | 39.1% (9/23) | 34.8% (8/23) | 39.1% (9/23) | 56.5% (13/23) |
Placebo | 40% (12/30) | 50% (15/30) | 43.3% (13/30) | 33.3% (10/30) | 43.3% (13/30) | 46.7% (14/30) | |
p = 0.518a | p = 0.621a | p = 0.095a | p = 0.012a | p = 0.095a | p = 0.506a | ||
Grade 1 Decreased 0.1% to <10% from baseline | Lithium | 34.8% (8/23) | 13% (3/23) | 8.7% (2/23) | 26.1% (6/23) | 17.4% (4/23) | 8.7% (2/23) |
Placebo | 23.3% (7/30) | 16.7% (5/30) | 20% (6/30) | 23.3% (7/30) | 30% (9/30) | 20% (6/30) | |
p = 0.495a | p = 0.264b | p = 0.229b | p = 0.817a | p = 0.233b | p = 0.229b | ||
Grade 2 Decreased 10 to <30% from baseline | Lithium | 26.0% (6/23) | 26.1% (9/23) | 43.5% (10/23) | 21.7% (5/23) | 34.8% (8/23) | 23% (6/23) |
Placebo | 26.7% (8/30) | 13.3% (5/30) | 30% (9/30) | 33.3% (10/30) | 13.3% (4/30) | 30% (9/30) | |
p = 0.971a | p = 0.164a | p = 0.765a | p = 0.484a | p = 0.145a | p = 0.814b | ||
Grade 3 Decreased ≥30 to <50% from baseline | Lithium | 8.7% (2/23) | 8.7% (2/23) | 8.7% (2/23) | 8.7% (2/23) | 8.7% (2/23) | 8.7% (2/23) |
Placebo | 0% | 0% | 3.3% (1/30) | 0% | 13.3% (4/30) | 3.3% (1/30) | |
p = 0.202b | p = 0.202b | p = 0.418b | p = 0.202b | p = 0.493b | p = 0.418b | ||
Grade 4 Decreased ≥50% from baseline | Lithium | 0% | 0% | 0% | 0% | 0% | 0% |
Placebo | 0% | 0% | 0% | 3.3% (1/30) | 0% | 0% | |
p = 574b | |||||||
Creatinine not measuredc | Lithium | 0% | 0% | 0% | 4.3% (1/23) | 0% | 0% |
Placebo | 0% | 10% (3/30) | 3.3% (1/30) | 3.3% (1/30) | 0% | 0% | |
p = 0.197b | p = 0.574b | p = 0.687b |